adesso (ADN1) Q3 2024 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 TU earnings summary
14 Jan, 2026Executive summary
Achieved record sales of €961.3 million for the first nine months of 2024, up 15% year-over-year, driven by strong organic growth and a 14% increase in average headcount.
EBITDA rose 24% year-over-year to €66.5 million, with Q3 EBITDA margin reaching 11.8% and improved capacity utilization.
Net income for 9M 2024 reached €2.5 million, a turnaround from a loss in the prior year period.
The company is on track to meet its full-year 2024 guidance, supported by improved utilization and an additional working day in Q4.
Focus remains on profitability and cautious optimism for 2025 amid macroeconomic and political uncertainties.
Financial highlights
Sales revenues grew 15% year-over-year to €961.3 million for 9M 2024; Q3 sales were €330.2 million, up 15% from Q3 2023.
EBITDA margin improved to 6.9% for 9M 2024 (up from 6.4%); Q3 margin reached 11.8%.
Earnings per share for 9M 2024 were €0.16, compared to -€0.05 in 9M 2023; Q3 EPS was €1.67, up from €0.86.
Net working capital reduced by 15% year-over-year, and net debt improved to -€101.5 million.
Free cash flow for 9M 2024 was -€30.7 million, a 64% improvement year-over-year, with factoring increased to €60 million.
Outlook and guidance
Full-year sales target of over €1.25 billion is within reach, with EBITDA expected between €80–110 million and a 7% margin.
Guidance confirmed for 2024, with strong demand for digitalization and software engineering services.
Q4 2024 benefits from one additional working day and potential license income.
Cautious optimism for 2025, with ongoing monitoring of macroeconomic and political uncertainties.
Latest events from adesso
- Sales up 11% in Q1 2025; margin recovery and stronger H2 earnings expected.ADN1
Q1 2025 TU9 Jul 2026 - Sales and EBITDA grew 12% and 34% in H1 2025, but free cash flow and equity ratio declined.ADN1
Q2 20258 Jul 2026 - 14% sales growth and margin gains in 2024 set the stage for further expansion in 2025.ADN1
H2 20248 Jul 2026 - Sales up 16% to €631.1m, but negative EPS and EBITDA guidance cut amid margin pressure.ADN1
H1 20248 Jul 2026 - Q1 2026 revenue up 13%, EBITDA up 58%, and net earnings positive amid strong sector growth.ADN1
Q1 202611 May 2026 - 2025 sales rose 14% to EUR 1.47B, with 30% EBITDA growth and a strong 2026 outlook.ADN1
Q4 202531 Mar 2026 - Sales, EBITDA, and EPS surged, with robust sector growth and guidance at the upper end.ADN1
Q3 202515 Nov 2025